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Objectives. To evaluate which factors can predict progression of atherosclerosis in 
Wegener’s granulomatosis (WG) patients. 
Methods. Twenty-three WG patients (14 men; age 47 ± 9 years, mean ± standard 
deviation) and 21 controls (12 men; age 47 ± 10 years) were included. Intima-media 
thickness (IMT) was determined by ultrasound, as measure for atherosclerosis. After 
median follow-up of 72 months (interquartile range: 66-76), IMT was repeated. 
Traditional risk factors for cardiovascular disease were determined, as well as levels of 
C-reactive protein (CRP) and endothelial activation markers, including 
thrombomodulin, vascular cell adhesion molecule-1 (VCAM-1) and von Willebrand 
factor (vWf). Disease-related factors were recorded from time of diagnosis until end of 
follow-up. 
Results. Maximum IMT at both visits was increased in patients compared to controls 
Patients had an increased prevalence of hypertension and increased levels of vWf and 
CRP. Progression of IMT was not different between patients and controls. IMT at 
follow-up was positively associated with age, blood pressure, CRP and VCAM-1, and 
negatively with HDL. During follow-up, disease activity was lower compared to the 
period from diagnosis until the first IMT measurement, and blood pressure and 
prevalence of dyslipidemia decreased in WG patients. Progression of IMT was not 
correlated to any risk factor measured. 
Conclusions. Maximum IMT was increased in WG patients compared to controls. 
Progression of IMT was not different between patients and controls, probably because 
disease activity was low and reduction of traditional risk factors was achieved during 
follow-up. We suggest that control of disease activity and treatment of traditional risk 
factors are important to prevent cardiovascular disease in WG. 
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INTRODUCTION 
Atherosclerosis is considered to result from an inflammatory process1;2, and various 
large prospective epidemiological studies have demonstrated that increased levels of 
inflammatory markers are predictive of future cardiovascular disease (CVD).3;4 
Inflammation is also one of the hallmarks of systemic autoimmune diseases such as 
Wegener’s granulomatosis (WG).5 Therefore, accelerated atherosclerosis, as well as 
endothelial activation and dysfunction, one of the earliest steps in atherosclerosis, 
might be expected in WG. Indeed, endothelial activation occurs in vivo in this disease, 
as demonstrated by increased serum levels of soluble intracellular adhesion molecule-
1, vascular cell adhesion molecule-1 (VCAM-1), and E-selectin.6 Furthermore, 
endothelial dysfunction measured using different techniques, including flow-mediated 
dilatation, laser Doppler fluxmetry and pulse wave velocity, has been described in 
WG.7-10 The prevalence of atherosclerosis, as assessed by intima-media thickness 
(IMT), is also increased in WG.11 This increased IMT could not be fully explained by 
the presence of traditional cardiovascular risk factors. Therefore, non-traditional risk 
factors are probably involved, including disease-related factors such as disease activity. 
The question remains which disease-related factors in particular are contributing most 
to this increased IMT in WG. A follow-up study measuring progression of IMT in 
relation to disease-related factors might solve this question. However, at present, no 
follow-up studies measuring IMT have been performed in WG. 
The aim of the present study was to assess the progression of IMT thickening of the 
common carotid artery (CCA) in WG patients and controls. In addition, we 
investigated the possible associations between this progression and traditional and non-
traditional risk factors, including disease-related factors, for atherosclerosis. A six year 
follow-up period for the IMT allowed us to compensate for small and slow changes 
over time in IMT which impede statistically sound conclusions in a relatively small 
number of WG patients. 
 
PATIENTS AND METHODS 
Subjects 
Of the 29 patients who participated in the study described previously11, 23 patients 
were included. Six patients were lost to follow-up; two patients died (due to urothelial 
cancer and massive haemoptysis, respectively), two patients had moved, and two 
patients withdrew informed consent. Pregnancy and active disease, defined as 
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Birmingham Vasculitis Activity score (BVAS) >112, were exclusion criteria at both 
visits. We recruited 21 healthy age- and sex-matched volunteers as controls. The local 
research ethics committee gave approval for the study, and informed consent was 
obtained from each participant. 
Hypertension was defined as systolic arterial pressure above 140 mmHg and/or 
diastolic arterial pressure above 90 mmHg, or use of antihypertensive drugs.13 
Dyslipidemia was diagnosed if plasma cholesterol exceeded 6.21 mmol/l, LDL 
cholesterol exceeded 3.36 mmol/l, triglycerides exceeded 2.26 mmol/l, or use of lipid-
lowering drugs.13 Furthermore, body mass index, smoking status, diabetes and family 
history of CVD (considered positive if first-degree relatives suffered from CVD before 
60 years of age) were recorded. 
We also assessed disease-related factors that might influence the development of 
atherosclerosis from time of diagnosis until end of follow-up in retrospective analyses. 
Data of medical records were used. The frequency of visits to our out-patient clinic is 
at least once in three months. As a measure of overall disease burden, cumulative 
BVAS was calculated by summing BVAS-score of each relapse. Mean CRP over a 
certain period was calculated and depicted as mg/l/day, as we divided the area under 
the curve by the particular period. In addition, we recorded cumulative prednisolone 
dose, proteinuria and creatinine clearance. 
All measurements recorded at entry (visit 1), including traditional and disease-related 
risk factors, were repeated after median follow-up (visit 2) of 72 months (interquartile 
range: 66-76) in patients and controls. 
 
Blood analyses 
Plasma lipid concentrations (cholesterol, HDL, LDL, and triglycerides) were measured 
by routine techniques.  
Additional serum and plasma samples for determination of levels of markers of 
endothelial activation and inflammation were stored at -20˚C until analysis. Serum 
levels of VCAM-1 (R&D Systems, Abingdon, UK) and thrombomodulin (Diaclone, 
Besançon, France) were measured according to the manufacturer’s instructions. Von 
Willebrand factor (vWf) and CRP were determined using in-house enzyme-linked 
immunosorbent assays as described previously.11 
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Measurements of intima-media thickness  
IMT was measured as described by de Groot et al.14 At visit 1 and visit 2, IMT was 
determined at the far wall of the left CCA approximately 1 cm proximal to the bulb 
using an acuson 128XP ultrasound with 7 MHz linear array transducers (Acuson Corp., 
Mountain view, USA). A B-mode image was obtained after which a probe was 
positioned perpendicular to the far wall, showing an intima-media complex over 
approximately one centimeter. Mean IMT (mean of the segment studied) and 
maximum IMT (highest IMT value found among the segment studied) were calculated. 
Progression of mean IMT was determined at the left CCA and defined as mean IMT at 
visit 2 minus mean IMT at visit 1 divided by time of follow-up in years. Progression of 
maximum IMT was similarly calculated. Coefficient of variation of IMT measurement 
of the CCA is approximately 5%.15 
 
Statistical methods 
Except when stated otherwise, values were expressed as mean ± standard deviation 
when variables were normally distributed. In case of a non-normal distribution values 
were expressed as median and interquartile range. Comparisons between patients and 
controls were made by two-sample t-tests or Mann-Whitney U tests for continuous 
variables and by chi-square analysis for categorical variables. The univariate 
correlation between IMT and other categorical variables was assessed by Spearman 
correlation coefficient. Comparisons between variables at visit 1 and visit 2 were made 
by paired-samples t-test or Wilcoxon signed ranks test for continuous variables and by 
McNemar analysis for categorical variables. Multiple linear regression analysis was not 
performed due to the small sample size. All analyses were performed using SPSS 12.0. 
A two-sided p value <0.05 was considered to indicate statistical significance. 
We performed a power analysis based on our previous study concerning IMT 
measurements in WG, in which mean IMT of 29 WG patients (0.72 ± 0.16 mm) were 
compared to mean IMT of 26 controls (0.66 ± 0.13 mm).11 Mean difference of mean 
IMT between patients and controls was 0.06 mm. We hypothesized that this enhanced 
increase in IMT in WG is due to the disease itself. To estimate a rate of progression, 
we divided this mean difference in IMT by the disease duration (mean 79 months), 
resulting in an estimated rate of progression of IMT of 0.009 mm/year in patients. 
Progression of IMT in controls was estimated at 0.001 mm/year.16 Power analyses 
revealed that at least 20 patients and 20 controls had to be included to detect a 
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difference in progression of mean IMT of 0.008 mm/year with a standard deviation of 
0.010 at a significance level of 0.05 with a power of 80%. 
 
RESULTS 
Risk factors and endothelial activation markers in patients and controls 
The demographic characteristics and traditional cardiovascular risk factors at both 
visits are shown in table 1. At both time points, patients and controls showed a 
comparable profile with respect to age, sex, body mass index, prevalence of diabetes, 
lipid levels, use of lipid-lowering drugs and positive family history of CVD. At visit 1, 
both systolic and diastolic blood pressure were higher in patients (p<0.001 and p =  
 
Table 1. Characteristics and endothelial activation in patients and controls 
 Visit 1 Visit 2 
Characteristics  Patients 
(n = 23) 
Controls 
(n = 21) 
Patients 
(n = 23) 
Controls 
(n = 21) 
Age, years  51 ± 13 47 ± 11  56 ± 14 52 ± 11  
Male sex, n (%) 14 (61%) 12 (57%)   
Body mass index, kg/m2 26 ± 4 25 ± 3 26 ± 5 25 ± 3 
Hypertension, n (%) 9 (39%)** 0 13 (57%)** 1 (8%) 
Blood pressure, mmHg 
      Systolic 
      Diastolic 
 
129 ± 16** 
78 ± 9** 
 
110 ± 15 
68 ± 8 
 
124 ± 15 
71 ± 9 
 
120 ± 11  
76 ± 8 
Antihypertensive drugs, n (%) 8 (35%)** 0 13 (57%)** 0 
Smoking, n (%) 1 (4%)* 6 (29%) 2 (9%) 2 (14%) 
Diabetes, n (%) 1 (4%) 0 1 (4%) 0 
Cholesterol, mmol/l 
      Total 
      LDL 
      HDL 
 
5.6 ± 1.0 
3.8 ± 0.8 
1.1 ± 0.3  
 
5.5 ± 0.9 
3.6 ± 0.9 
1.1 ± 0.3 
 
4.9 ± 0.7 
3.0 ± 0.8 
1.4 ± 0.4 
 
5.0 ± 0.8 
3.3 ± 0.8 
1.5 ± 0.3 
Dyslipidemia, n (%) 19 (83%) 11 (53%) 11 (48%) 12 (57%) 
Lipid-lowering drugs, n (%) 2 (8%) 0 5 (22%) 1 (8%) 
Family history CVD, n (%) 6 (26%) 9 (43%) 6 (26%) 9 (43%) 
Creatinine, µmol/l 101 (89-114) ND 93 (78-112)** 75 (68-80) 
Creatinine clearance, ml/min 92 (80-107) ND 78 (71-98)** 112 (99-126) 
TM, ng/ml 5.6 (4.8-8.1) 5.5 (4.5-6.5) 5.1 (4.3-7.6)** 4.1 (3.7-4.6) 
VCAM-1, ng/ml 277 (234-333) 278 (223-330) 315 (255-398) 285 (253-318) 
vWf, % 115 (85-194)* 79 (60-120) 93 (77-199)** 68 (45-107) 
CRP, mg/l 2.2 (1.5-8.6)** 0.6 (0.4-3.1) 4.5 (2.5-22.4)** 1.9 (0.8-4.8) 
Unless otherwise indicated, data are expressed as mean ± standard deviation when normally distributed and as 
median (interquartile range) when non-normally distributed; *: p<0.05, **: p<0.01 compared to controls.  
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0.002, respectively), despite more frequent use of antihypertensive drugs (p = 0.003). 
Renal function was reduced in patients compared to controls at visit 2 (p<0.001). 
Concerning endothelial activation markers, level of CRP and vWf were increased in 
patients at both visits (p = 0.005 and p = 0.02 at visit 1, p = 0.02 and p = 0.01 at visit 2, 
respectively). At visit 2, also levels of TM were elevated in patients (p = 0.002). 
During follow-up, some traditional risk factors changed, especially in patients (table 1). 
At visit 2, more patients were on antihypertensive drugs (p = 0.06), and diastolic (p = 
0.004) blood pressure decreased in this period. Furthermore, prevalence of 
dyslipidemia decreased (p = 0.02), as levels of cholesterol and levels of LDL decreased 
(p = 0.002, and p<0.001, respectively) and levels of HDL increased (p<0.001). Use of 
lipid-lowering drugs did not significantly change during follow-up. 
 
Disease-related factors 
The disease duration from diagnosis until the moment of the first IMT measurement 
was 43 (21-86) months. Disease-related factors are depicted in table 2. In addition, at 
visit 1, three patients used cyclophosphamide, and two used methotrexate. At visit 2, 
no patients used cyclophosphamide or methotrexate anymore, and three used 
mycophenolate mofetil. Parameters of disease activity, including cumulative BVAS, 
cumulative prednisolone dose, and mean CRP levels, were higher in the period before 
visit 1 compared to the period of follow-up (table 2). 
 
Table 2. Disease-related factors of WG patients (n = 23) 
 Visit 1 Visit 2 During  follow-up 
Disease duration, months 43 (21-86) 117 (90-161)*  
Proteinuria, mg/l 0.2 (0-0.5) 0.2 (0-0.5)  
Patients with relapse, n (%) 







Cumulative BVAS 27 (21-49) 37 (26-66)** 0 (0-18)** 
CRP, mg/l/day 6.7 (1.8-11.7) 5.0 (1.9-7.6) 3.8 (1.5-6.8)* 
Current prednisolone use, n (%) 
Daily dose, mg 
Ever prednisolone use, n (%) 

















Azathioprine use, n (%) 










At entry and after follow-up, IMT of the left CCA was determined. Data are shown in 
table 3 and figure 1A. At both visits, maximum IMT was increased in WG patients (p 
<0.05). Mean IMT over this segment did not differ between controls and patients.  
 
Table 3. Intima-media thickness of patients and controls 
 Visit 1 Visit 2 
 WG (n = 23) Controls (n = 21) WG (n = 23) Controls (n = 21) 
Mean IMT, mm 0.67 (0.54-0.77) 0.64 (0.57-0.75) 0.69 (0.63-0.86) 0.68 (0.57-0.80) 
Max IMT, mm 0.85 (0.73-0.93)* 0.73 (0.66-0.85) 0.85 (0.81-1.01)* 0.77 (0.66-0.85) 
Values are depicted as median (interquartile range); *: p<0.05 compared to controls. 
 
As shown in figure 1B, progression of mean IMT of the left CCA was 0.005 (0.001-
0.023) mm/year in patients and 0.004 (-0.006-0.021) mm/year in controls (p = 0.46). 
Progression of maximum IMT was also not different between patients and controls 
(0.014 (-0.001-0.025) mm/year vs. 0.013 (-0.013-0.030) mm/year, respectively). 
 















Figure 1. Intima-media thickness (IMT) in patients and controls. 
A. Maximum IMT of the left common carotid artery is increased in Wegener’s granulomatosis (WG) 
patients compared to controls at both visits. No differences in mean IMT are found.  
B. Progression of mean IMT and maximum IMT after a follow-up period of approximately six years did not 
differ between WG patients compared to controls. Open symbols represent controls and closed symbols 
represent WG patients.  
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Univariate analyses of risk factors 
In controls mean IMT of the CCA as measured at visit 1 was correlated with the 
following variables at visit 1: age (r = 0.67, p = 0.001), diastolic blood pressure (r = 
0.57, p = 0.02), and levels of cholesterol (r = 0.56, p = 0.008). In patients, mean IMT at 
visit 1 was associated with age (r = 0.53, p = 0.005), diastolic blood pressure (r = 0.41, 
p = 0.04) and levels of VCAM-1 (r = 0.46, p = 0.02). Although cumulative CRP values 
during follow-up tended to correlate with progression of IMT (r = 0.37, p = 0.1), no 
significant correlations were found between progression of IMT and all individual risk 
factors included.  
Mean IMT at visit 2 was correlated to variables at visit 1 to investigate predictive 
factors of increased IMT after follow-up. Mean IMT at visit 1 was correlated with age 
(r = 0.53, p < 0.001), systolic (r = 0.24, p = 0.03) and diastolic (r = 0.45, p = 0.004) 
blood pressure, levels of HDL (r = -0.44, p = 0.003), levels of VCAM-1 (r = 0.39, p = 
0.02) and levels of CRP (r = 0.36, p = 0.03) using data of controls and patients 
together. 
 
Disease activity and intima-media thickness 
To investigate whether disease activity would influence progression of IMT, we 
compared patients who experienced one or more relapses during follow-up (n = 11) to 
those patients without relapses (n = 12). Twenty relapses occurred during follow-up. 
Median BVAS score of these relapses during follow-up was lower compared to BVAS 
score of relapses in the period from diagnosis until visit 1 (9 (8-12) vs. 16 (9-18), p = 
0.02). No differences were found in traditional or non-traditional risk factors, including 
EC activation markers between patients with relapses during follow-up compared to 
patients without relapses (data not shown). Progression of IMT was not different 
between both patient groups (the change in mean IMT was 0.004 (-0.005-0.019) 
mm/year vs. 0.012 (0.002-0.042) mm/year, p = 0.21, and, the change in maximum IMT 
was 0.006 (-0.006-0.025 mm/year vs. 0.015 (0.008-0.048) mm/year, p = 0.17, in 









This study is the first which measures IMT longitudinally in WG patients. At entry, 
patients had an increased maximum IMT of the left CCA compared to controls. After 
follow-up, maximum IMT was still increased in patients. However, progression of IMT 
among patients and controls was similar. 
We performed a follow-up study to investigate whether WG patients are prone to 
accelerated progression of IMT. This hypothesis could not be confirmed, as no 
increased progression of IMT could be detected in WG. In addition, we compared 
patients who had one or more relapses during follow-up to those without relapses, 
expecting that patients with relapses would have an increased progression of IMT. 
However, no such increased IMT was found in these patients. 
Several explanations for these findings can be mentioned. First, disease-related factors 
might not have been sufficiently present to accelerate atherosclerosis. Disease activity 
was low during follow-up compared to the period from diagnosis until visit 1, as 
reflected by lower parameters of disease activity, including cumulative BVAS, mean 
CRP levels and cumulative prednisolone dose during follow-up. This also might 
explain the fact that even in patients with relapses during follow-up no progression of 
IMT was found, because relapses during follow-up were less severe than relapses 
before visit 1, as demonstrated by lower BVAS scores during follow-up. 
Secondly, traditional risk factors were more adequately treated during follow-up, 
presumably because more attention is being paid to traditional risk factors in WG 
patients in recent years. At visit 2, blood pressure was better regulated. Also, lipid 
levels improved in patients, as levels of cholesterol and LDL significantly decreased 
and levels of HDL significantly increased. More awareness and treatment of traditional 
risk factors of CVD in WG is comparable to the trend seen in other systemic 
autoimmune diseases, for example systemic lupus erythematosus.17-19 
We also aimed to assess predictors of progression of IMT. No correlations could be 
detected between progression of IMT and risk factors included in this study. However, 
when we analysed which factors at visit 1 could predict increased mean IMT at visit 2, 
we found that IMT at visit 2 positively correlated to age and blood pressure at visit 1, 
and negatively to levels of HDL. This emphasizes that traditional risk factors are of 
influence and should be adequately treated. Furthermore, positive correlations were 
found between IMT and levels of CRP and VCAM-1, indicating that inflammation and 
endothelial activation are implicated in atherosclerosis. Indeed, CRP has been found to 
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be an independent prognostic marker for CVD20, and levels of VCAM-1 have been 
demonstrated to be independent predictors of long-term clinical outcomes, including 
CVD in diabetic patients.21;22  
Our study has some limitations. First, our sample size is rather small. To detect 
possible differences in progression of IMT, we compensated for this relatively small 
number by a long follow-up period of six years. Secondly, although measuring the 
CCA has a better reproducibility and should have made it easier to reliably detect small 
differences in increases in IMT between WG patients and controls, atherosclerotic 
lesions, especially plaques, often appear later in the CCA than in the ICA or bulb.23;24 
Therefore, measuring only the CCA has the risk of missing more accelerated progress 
in the other segments. Benedetto et al recently showed that only new plaque formation 
in the bulbar area, and not IMT, was independently correlated to cardiovascular events 
in patients with end-stage renal disease.25 It might be suggested to measure progression 
of IMT in all segments, as well as to include plaque score in further studies. 
In conclusion, although IMT was increased in WG patients compared to controls at 
entry, no accelerated development of atherosclerosis in WG could be demonstrated 
during a follow-up of approximately six years. This might be explained by the fact that 
during follow-up disease activity was low and traditional risk factors were more 
adequately treated. These data suggest that control of disease activity and reduction of 
traditional risk factors may result in prevention of overt CVD in WG patients. 
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